Toripalimab: recurrent or metastatic nasopharyngeal cancerThe same nasopharyngeal cancer medicine,
at a much lower published price in China.
For 240mg of the same medicine, the published Chinese drug cost is approximately ¥2,439 versus a historical US WAC of approximately US $8,892. The difference is substantial, but the years and pricing bases differ and neither is a current patient quote. If you meet treatment criteria after recurrent or metastatic nasopharyngeal cancer, this potential room in your drug budget can inform ongoing treatment planning.
Free initial service consultation · Understand your options and budget before you travel
- China: reference cost for 240mg
- RMB 2,438.64 (80mg × 3 vials; published in 2026)
- US: historical WAC for one 240mg vial
- US $8,892.03 (2023-11-27)
The same drug and total dose, with different packaging and years; not current international patient quotes. WAC is not what patients actually pay. The 2023 study comparator was chemotherapy plus placebo and does not support switching medicines after immunotherapy resistance. View the evidence
The Chinese price was published by Tungwah on 2026-06-26; the US figure is historical WAC from 2023-11-27. Same drug and dose, different packaging. WAC is not actual payment; neither is a current quote or full treatment cost. View sources
The same medicine, with more room in a long-term drug budget
For eligible patients with nasopharyngeal cancer, the published price difference for the same medicine is a specific reason to consider care in China. The total budget must also cover combination treatment, return trips and follow-up.
For ongoing treatment, calculate the drug cost difference
The published Chinese cost for 240mg is approximately RMB 2,439. Comparing this with historical US WAC can help explore potential drug budget savings, but cannot promise actual savings.
First-line combination therapy to seek longer disease control
Toripalimab combined with gemcitabine and cisplatin has demonstrated a survival benefit. Later-line monotherapy and treatment after immunotherapy resistance require separate assessment.
Include the Chinese cost for the same 240mg dose in your budget
Chinese figures assume fully self-funded foreign patients without Chinese health insurance or free-drug assistance, alongside historical US WAC (wholesale acquisition cost). Chemotherapy, infusions and reassessments must be included in the treatment budget you prepare.
- China: 80mg × 1 vial
- RMB 812.88, published by Tungwah Hospital on 2026-06-26
- China: 80mg × 3 vials = 240mg
- RMB 2,438.64, for toripalimab alone
- US: LOQTORZI 240mg/6mL × 1 vial
- US $8,892.03 (approximately $8,892), WAC announced 2023-11-27
- Chemotherapy, infusions, laboratory tests and accommodation
- Additional; an itemised hospital quote based on the regimen is needed
These published prices cover the same drug and total dose with different packaging and years. Neither is a current international patient quote or full-course price; WAC is not the amount a patient actually pays. No currency conversion or savings percentage is calculated. First-line dosing is every 3 weeks, and costs accumulate with continued treatment.
Finding treatment that fits you
starts with the reports you already have.
Clarifying your disease type and previous treatment helps establish whether this option could form part of a plan for you.
- First-line settingLocally recurrent or metastatic nasopharyngeal cancer, considering toripalimab with gemcitabine and cisplatin.
- Later-line settingChinese monotherapy approval covers failure of at least two prior lines of systemic treatment; US later-line criteria cannot simply be applied.
- Tolerance requirementsAssess kidney function, hearing and immune disease history. If local curative treatment remains possible, discuss surgery or radiotherapy first.
Adding immunotherapy to seek longer disease control and survival
The first-line JUPITER-02 results compare toripalimab plus gemcitabine and cisplatin with the same chemotherapy plus placebo. Benefits cannot be directly applied to later-line monotherapy or switching after immunotherapy resistance.
- Hazard ratio for death
- 0.63 (95% confidence interval 0.45–0.89)
- Maintenance phase
- Continue study medication after chemotherapy, for up to 2 years in the study
- Number enrolled
- 289 patients
- Median progression-free survival
- 21.4 months versus 8.2 months
- 3-year overall survival
- 64.5% versus 49.2%
This does not mean everyone gains the same length of time; first-line combination efficacy cannot be cited for later-line monotherapy.
You do not need to book flights first.
Clarify treatment and costs before you travel.
Tell us your diagnosis, previous treatments and main concerns. We help you communicate about Shanghai consultation requirements, budgets and travel arrangements.
- Bring pathology reports and slides available for review to confirm the disease being treated
- Provide imaging before and after recurrence and EBV DNA results to explain changes in disease status
- Organise radiotherapy plans, previous medicines and response records to distinguish first-line and later-line options
- Provide liver, kidney and thyroid tests and immune disease history for a medication safety assessment
Start the first conversation with the records you already have.
You do not need to arrange new tests yourself for an initial consultation.
Get answers to the questions that matter to you
before you travel.
Costs, potential benefit and further treatment deserve specific answers before departure.
Is approximately RMB 2,439 the total cost of one treatment?
No. It is the 240mg drug cost of RMB 2,438.64, calculated as 80mg × 3 vials from Tungwah's published price on 2026-06-26. It is a fully self-funded reference without insurance or assistance, not a current international patient quote. Chemotherapy, infusion, tests and accommodation are additional. The US $8,892.03 figure from 2023-11-27 is historical WAC, not the amount patients actually pay.
Can I switch to this medicine after previous PD-1 treatment?
A lower price is not grounds to assume another drug in the same class will remain effective. Timing of resistance and subsequent options must be assessed. Chinese later-line monotherapy requires failure of at least two prior systemic treatment lines; US later-line criteria cannot simply be applied.
Which symptoms during treatment need prompt medical attention?
Seek prompt medical attention for breathlessness or fever. Risks include immune-mediated pneumonitis, hepatitis and endocrine abnormalities, as well as chemotherapy-related bone marrow suppression and kidney injury.
Can treatment be completed in one trip?
Usually not. First-line dosing is every 3 weeks, with ongoing treatment and imaging reassessment, so costs accumulate. Arrange drug supply, prescriptions and management of adverse effects before returning home.
Build ongoing treatment costs into a practical next step.
Starting with your condition and budget, we help communicate about consultations and treatment arrangements in Shanghai.
The initial service consultation is free; the treating doctor assesses your specific medical plan.
Sources and image credits
Information is compiled from public approval documents, studies and prices and does not replace an individual medical assessment. Research and cost figures each have a defined scope; published prices are not personal international patient quotes. Costs are discussed on a self-funded basis without Chinese health insurance or free-drug assistance.
- Junshi: Chinese first-line and later-line approvals for nasopharyngeal cancer · 2021-11-29
- JAMA: JUPITER-02 randomised trial · 2023-11-28
- Zhejiang Hospital: published price for toripalimab 80mg · Verified 2026-10-03
- Dongguan Tungwah Hospital drug price publication (original official table) · 2026-06-26
- Sun Yat-sen University Cancer Center: Mai Haiqiang · Verified 2026-10-03
- Sir Run Run Shaw Hospital pulmonary toxicity information: toripalimab · Verified 2026-10-03
- Coherus 2023 Form 10-K: LOQTORZI single-vial WAC of $8,892.03 announced 2023-11-27 (page 6 of main text) · 2024-03-15
- Original FDA 2023 prescribing information: LOQTORZI 240mg/6mL single-use vial · 2023-10-27